Dark Horse Consulting Group Inc.
Sanjin Zvonić has a diverse work experience spanning several industries. Sanjin currently holds the position of Senior Vice President, Business Development at Dark Horse Consulting Group Inc. Prior to this, they worked as a Practice Expert and Vice President, Business Development at the same company. Sanjin also served as a Principal at Dark Horse Consulting Group Inc.
In addition to their roles at Dark Horse Consulting Group Inc., Sanjin Zvonić has also worked as an Advisory Board Member at Artemis Factor and as Vice President, Product Development and Manufacturing at WindMIL Therapeutics. Sanjin held the position of Senior Director, Business Leader, Clinical & Commercial Manufacturing at Hitachi Chemical Advanced Therapeutics Solutions, LLC.
Sanjin Zvonić has a strong background in the biotechnology and healthcare sector. Sanjin previously worked at Novartis as a Senior Fellow, TRD, Cell & Gene Therapies Unit, where they were responsible for process and product development of a late-stage cell therapy product. Before that, they held various roles at Progenitor Cell Therapy, Tulane University, LSU Health Sciences Center, and Pennington Biomedical Research Center.
Overall, Sanjin Zvonić's work experience showcases their extensive expertise in business development, product development, manufacturing, and process development within the biotechnology and healthcare industry.
Sanjin Zvonić earned a Bachelor of Science degree in Biochemistry from Louisiana State University from 1996 to 2000. Following that, they pursued a Ph.D. in Cell & Molecular Biology, Human Nutrition at the same institution, completing it from 2000 to 2004.
This person is not in any offices
Dark Horse Consulting Group Inc.
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and enginnering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.